Advertisement
Advertisement
MBX
MBX Biosciences, Inc. Common Stock
65.59
USDSponsored
-2.23
-3.28%
Aug 10, 14:37 UTC -4
Open
MBX Earnings Reports
Positive Surprise Ratio
MBX beat 6 of 8 last estimates.
75%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.75
Implied change from Q2 26 (Revenue/ EPS)
--
/-3.85%
Implied change from Q3 25 (Revenue/ EPS)
--
/+19.05%
MBX Biosciences, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, MBX reported earnings of -0.78 USD per share (EPS) for Q2 26, missing the estimate of -0.63 USD, resulting in a -22.16% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.55% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.75 USD, with revenue projected to reach -- USD, implying an decrease of -3.85% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Apogee Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.13
Surprise
-4.39%
Tarsus Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.21
Actual
-$0.43
Surprise
-101.03%
Trevi Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.11
Surprise
+2.22%
Axsome Therapeutics, Inc
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.86
Actual
-$0.99
Surprise
-14.90%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
Lexicon Pharmaceuticals, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.06
Surprise
-17.19%
Lineage Cell Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-3.81%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
MAIA Biotechnology, Inc.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.13
Surprise
-15.86%
FAQ
What were MBX Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, MBX Biosciences, Inc. Common Stock reported EPS of -$0.78, missing estimates by -22.16%, and revenue of $0.00, 0% as expectations.
How did the market react to MBX Biosciences, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -0.55%, changed from $67.48 before the earnings release to $67.11 the day after.
When is MBX Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for MBX Biosciences, Inc. Common Stock's next earnings report?
Based on 7
analysts, MBX Biosciences, Inc. Common Stock is expected to report EPS of -$0.75 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement